Breaking Finance News

Stifel disclosed Vectrus (LON:VEC), bumping down its price target to 22.00GBX earlier today

Yesterday Vectrus (LON:VEC) traded -1.91% lower at 27.63GBX. The company’s 50-day moving average is 139.23GBX and its 200-day moving average is 155.59GBX. The last stock close price is down -11.11% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 522,001 shares of the stock were exchanged, down from an average trading volume of 1,878,600

Reporting a potential downside of -0.20%, Stifel dropped the price target of Vectrus (LON:VEC) to 22.00GBX

On 9/19/2016, Numis released a statement about Vectrus (LON:VEC) upped the target price from 246.00GBX to 252.00GBX that suggested an upside of 0.73%.

See Chart Below

Vectrus (LON:VEC)

Vectrus has a 52 week low of 122.90GBX and a 52 week high of 200.10GBX with a P/E ratio of 115.25 The company’s market cap is currently 0 GBX.

In addition to Stifel reporting its target price, a total of 6 firms have issued a report on the stock. The consensus target price is 215.67GBX with 4 firms rating the stock a strong buy, 2 firms rating the stock a buy, 1 firm rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell.

About Vectrus (LON:VEC)

Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company's products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) – LABA-LAMA; Seebri Breezhaler (EU and RoW) – LAMA; AirFluSal Forspiro (EU and RoW) – ICS-LABA; ADVATE (Global) – Antihaemophilic Factor (Recombinant); Adept (Global) – Icodextrin; Anoro Ellipta (Global) – LAMA-LABA; Relvar Ellipta/Breo Ellipta (Global) – ICS-LABA, and Incruse Ellipta (Global) – LAMA. Its product pipeline includes VR588, VR475, VR647, VR942, VR179, VR736, VR096, VR876, VR315, VR506, VR632, Seebri Neohaler and VR465. Its dry powder inhalers (DPI) include GyroHaler, Lever-operated, Open-inhale-close and Unit Dose DPI. Its smart nebuliser delivery systems provide targeted inhalation therapy for applications where precise and targeted delivery of a drug to the lungs is needed. Its smart nebulizer delivery systems include AKITA JET and FOX.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.